Rapid Cancer Pain Management Growth to Push Global Revenue to $7 Bn by 2019

Wednesday 7 August 2013, Amsterdam

In 2012, the global pain management market was estimated at $35.7 bn, representing a Compound Annual Growth Rate (CAGR) of 2.9% between 2006 and 2012. The approval of products such as Lyrica (pregabalin), Cymbalta (duloxetine), and Abstral (fentanyl) drove the growth in the market in the historic period. By 2019, the global pain management market is forecast to generate sales of $48.8 bn, representing a CAGR of 4.6% between 2012 and 2019.

The cancer pain market is expected to increase at the highest rate, at a CAGR of 9.1% over the forecast period. This will be followed by the post-operative pain market, with a CAGR of 8.2%. The global pain management market is expected to witness a series of patent expiries between 2013 and 2018, which includes some top-selling drugs such as Cymbalta, Lyrica and Celebrex (celecoxib). While the current pain management market has a healthy pipeline and prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition.